Skytrofa (Lonapegsomatropin-Tcgd) Patent Expiration, LOE Window & CMS Spending

Skytrofa (Lonapegsomatropin-Tcgd) by Ascendis Encocrinology Div A/S: Biologic BLA (Purple Book Regime), 0 AB generics, $118.4M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAscendis Encocrinology Div A/S
FDA Application & PathwayB761177 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$118.4M
2024 Medicare Part D Spend$159K
2024 Medicaid Spend$118.2M
Reported Wholesale Price Change (CA SB 17)9 WAC filings (max 16.3% 2-yr change)